AI assistant
Sending…
CVS HEALTH Corp — Director's Dealing 2007
Apr 4, 2007
29875_dirs_2007-04-04_2eb1d014-ab4a-4fb1-8de2-7220c2fba801.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CVS/CAREMARK CORP (CVS)
CIK: 0000064803
Period of Report: 2007-04-02
Reporting Person: MCLURE HOWARD A (President, Caremark Pharm Serv)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2007-04-02 | Stock Option | $34.42 | A | 208750 | Acquired | 2014-04-02 | Common Stock (208750) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $6.46 | 2010-11-15 | Common Stock (93692) | 93692 | Direct |
| Stock Option | $7.04 | 2011-11-07 | Common Stock (187391) | 187391 | Direct |
| Stock Option | $9.78 | 2013-04-02 | Common Stock (65579) | 65579 | Direct |
| Stock Option | $17.08 | 2014-05-10 | Common Stock (374717) | 374717 | Direct |
| Stock Option | $20.23 | 2015-03-01 | Common Stock (374879) | 374879 | Direct |
| Stock Option | $23.23 | 2015-06-27 | Common Stock (260459) | 260459 | Direct |
| Stock Option | $27.12 | 2016-03-01 | Common Stock (234212) | 234212 | Direct |
Footnotes
F1: Option acquired in connection with the merger of Caremark Rx, Inc. with a subsidiary of CVS Corporation and the conversion of Caremark Rx, Inc. stock option to CVS/Caremark Corporation stock option. Option is 100% exercisable as of the date of the merger.
F2: Option becomes exercisable in three equal annual installments, commencing 4/2/2008.
More from CVS HEALTH Corp
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 18
Regulatory Filings
2026
May 7
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Major Shareholding Notification
2026
Apr 30
Annual Report
2026
Apr 3
Proxy Solicitation & Information Statement
2026
Apr 3
Proxy Solicitation & Information Statement
2026
Apr 3